ES2378097T3 - Proteínas de unión al factor de crecimiento de hepatocitos (HGF) - Google Patents

Proteínas de unión al factor de crecimiento de hepatocitos (HGF) Download PDF

Info

Publication number
ES2378097T3
ES2378097T3 ES07795607T ES07795607T ES2378097T3 ES 2378097 T3 ES2378097 T3 ES 2378097T3 ES 07795607 T ES07795607 T ES 07795607T ES 07795607 T ES07795607 T ES 07795607T ES 2378097 T3 ES2378097 T3 ES 2378097T3
Authority
ES
Spain
Prior art keywords
seq
acid sequence
heavy chain
variable region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07795607T
Other languages
English (en)
Spanish (es)
Inventor
May Han
S. Kirk Wright
William M. Winston, Jr.
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveo Pharmaceuticals Inc
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2378097T3 publication Critical patent/ES2378097T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES07795607T 2006-06-02 2007-06-01 Proteínas de unión al factor de crecimiento de hepatocitos (HGF) Active ES2378097T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US810714P 2006-06-02
US86046106P 2006-11-21 2006-11-21
US860461P 2006-11-21
PCT/US2007/012950 WO2007143098A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (1)

Publication Number Publication Date
ES2378097T3 true ES2378097T3 (es) 2012-04-04

Family

ID=38802082

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07795607T Active ES2378097T3 (es) 2006-06-02 2007-06-01 Proteínas de unión al factor de crecimiento de hepatocitos (HGF)

Country Status (15)

Country Link
US (5) US7659378B2 (enExample)
EP (2) EP2380908A1 (enExample)
JP (2) JP4560582B2 (enExample)
KR (1) KR101196184B1 (enExample)
AR (1) AR061170A1 (enExample)
AT (1) ATE533787T1 (enExample)
AU (1) AU2007254853B2 (enExample)
BR (1) BRPI0712223A2 (enExample)
CA (1) CA2654019A1 (enExample)
ES (1) ES2378097T3 (enExample)
IL (2) IL195038A0 (enExample)
MX (1) MX2008015138A (enExample)
NO (1) NO20085422L (enExample)
NZ (1) NZ573819A (enExample)
WO (1) WO2007143098A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4560582B2 (ja) * 2006-06-02 2010-10-13 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
HRP20151261T1 (hr) 2007-07-02 2016-01-01 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za lijeäśenje i dijagnosticiranje raka
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0912035A2 (pt) 2008-05-29 2017-05-23 Galaxy Biotech Llc anticorpo monoclonal, composição farmacêutica, uso de uma composição farmacêutica, mab de camundongo na forma quimérica ou humanizada, e, anticorpo humanizado
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
CA2730201C (en) 2008-07-10 2019-02-05 Toray Industries, Inc. Anti-cd179b antibody
PL3290052T3 (pl) 2008-11-07 2020-06-29 Galaxy Biotech, Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
AU2009314111A1 (en) * 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. BetaGI-IgG intron for enhanced anti-IGF1 R expression
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR078254A1 (es) * 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012004415A (es) * 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
SG190362A1 (en) * 2010-11-24 2013-06-28 Glaxo Group Ltd Multispecific antigen binding proteins targeting hgf
JP6185463B2 (ja) 2011-07-15 2017-08-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ結合剤およびその使用法
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EA032038B1 (ru) 2012-07-13 2019-03-29 Онкомед Фармасьютикалс, Инк. Rspo3-связывающие агенты и их применение
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
KR20150140685A (ko) * 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
EP3180027A4 (en) * 2014-08-15 2018-01-10 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
JP2017528523A (ja) 2014-09-16 2017-09-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 線維性疾患の治療
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
WO2016065329A1 (en) * 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
KR102364249B1 (ko) 2016-03-28 2022-02-17 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-ryk 항체 및 이의 사용 방법
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
AU2018281045A1 (en) 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
EP3638299A4 (en) * 2017-06-15 2021-03-31 Memorial Sloan-Kettering Cancer Center ANTI-L1-CAM ANTIBODIES AND THEIR USES
CN118638788A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
WO2020191293A1 (en) * 2019-03-20 2020-09-24 Javelin Oncology, Inc. Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
US20220275368A1 (en) 2019-08-12 2022-09-01 Interna Technologies B.V. New treatments involving mirna-193a
CN115461461A (zh) 2020-02-28 2022-12-09 因特尔纳技术有限公司 用于促进免疫原性细胞死亡的miRNA-193a
WO2021195469A1 (en) * 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
AU1598801A (en) 1999-11-09 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The HGF-SF monoclonal antibody combinations
MXPA05000511A (es) * 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
KR20080026562A (ko) * 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
SG158112A1 (en) * 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
JP4560582B2 (ja) * 2006-06-02 2010-10-13 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법

Also Published As

Publication number Publication date
AU2007254853B2 (en) 2011-11-17
US8575318B2 (en) 2013-11-05
IL219655A0 (en) 2012-06-28
EP2029627A2 (en) 2009-03-04
WO2007143098A8 (en) 2009-01-08
MX2008015138A (es) 2009-01-28
KR20090026315A (ko) 2009-03-12
JP4560582B2 (ja) 2010-10-13
US7659378B2 (en) 2010-02-09
AU2007254853A2 (en) 2009-02-12
EP2380908A1 (en) 2011-10-26
ATE533787T1 (de) 2011-12-15
EP2029627B1 (en) 2011-11-16
BRPI0712223A2 (pt) 2012-07-10
US20140178934A1 (en) 2014-06-26
HK1129394A1 (en) 2009-11-27
AU2007254853A1 (en) 2007-12-13
NZ573819A (en) 2011-09-30
US20080038257A1 (en) 2008-02-14
NO20085422L (no) 2009-02-27
JP5528246B2 (ja) 2014-06-25
KR101196184B1 (ko) 2012-11-01
US20100173361A1 (en) 2010-07-08
US8268315B2 (en) 2012-09-18
WO2007143098A2 (en) 2007-12-13
AR061170A1 (es) 2008-08-06
US20130203970A1 (en) 2013-08-08
US7935502B2 (en) 2011-05-03
IL195038A0 (en) 2011-08-01
WO2007143098A3 (en) 2008-06-12
JP2009539348A (ja) 2009-11-19
JP2010246565A (ja) 2010-11-04
CA2654019A1 (en) 2007-12-13
US20110236377A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
EP2029627B1 (en) Hepatocyte growth factor (hgf) binding proteins
EP2027156B9 (en) Hepatocyte growth factor (hgf) binding proteins
US10570201B2 (en) Anti-CD47 antibodies and methods of use
ES3030258T3 (en) Anti-pro/latent-myostatin antibodies and uses thereof
ES2877548T3 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
ES3058239T3 (en) Multi-specific wnt surrogate molecules and uses thereof
ES2647389T3 (es) Anticuerpos para GDF8 humano
ES2881602T3 (es) Conjugados de anticuerpo-fynómero
JP2025133893A (ja) 抗ｔｒｅｍ２抗体及びその使用方法
ES2962824T3 (es) Anticuerpos contra FcRn y procedimientos de uso de los mismos
ES2713505T3 (es) Anticuerpos anti-TGF-beta modificados genéticamente y fragmentos de unión a antígeno
ES2744526T3 (es) Anticuerpos anti-MCAM y métodos de uso asociados
ES2784131T3 (es) Polipéptidos de unión beta del receptor PDGF
ES2865112T3 (es) Anticuerpos de unión a protofibrillas A-beta mejorados
ES2924282T3 (es) Moléculas de transporte a través de la barrera hematoencefálica y usos de las mismas
JP2009539347A5 (enExample)
ES2673869T3 (es) Anticuerpos frente a ligandos del receptor B1 de bradicinina
TWI908724B (zh) TrkA的抗體及其應用
ES2802176T3 (es) Nuevos anticuerpos dirigidos contra el receptor IIB de Fc gamma y el receptor de Fc épsilon
ES2566343T3 (es) Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos
JP2022547018A (ja) 抗ｃｘｃｒ２抗体およびその使用
ES2359176T3 (es) Proteínas de unión al factor de crecimiento de hepatocitos( hgf).
HK1129394B (en) Hepatocyte growth factor (hgf) binding proteins
HK1129395B (en) Hepatocyte growth factor (hgf) binding proteins
BR112022000628B1 (pt) Anticorpo anti-tigit isolado ou fragmento de ligação ao antígeno do mesmo, moléculas de ácido nucleico isoladas, vetor recombinante ou de expressão, composição farmacêutica, combinação, usos dos mesmos, kit, artigo de manufatura, e método para detecção de tigit em uma amostra